Publicacións en colaboración con investigadores/as de Thomas Jefferson University (8)

2021

  1. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma

    Cancer Medicine, Vol. 6, Núm. 1, pp. 36-44

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

    Annals of Oncology, Vol. 26, Núm. 4, pp. 774-779

2014

  1. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

    Biomarker Research, Vol. 2, Núm. 1

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544